Decision

Teva Canada Limited v. Janssen Inc., 2017 FC 434 (Bortezomib*)

Justice Locke - 2017-05-31

Read full decision. Automatically generated summary:

The plaintiffs by counterclaim, Millennium Pharmaceuticals Inc., Janssen Inc., Cilag GmbH International, Cilag AG and Janssen Pharmaceutica NV, seek leave to amend their defence and counterclaim. The notice of motion was accompanied by a draft Second Amended Statement of Defence and Counterclaim including the proposed amendments. The parties agree on many of the proposed amendments. They disagree only on the proposed addition of new paragraphs 9.1 to 9.12.

Decision relates to:

  • T-944-15 - TEVA CANADA LIMITED v. JANSSEN INC. ET AL.

 

Canadian Intellectual Property